Crescent Biopharma, Inc.
Income Statement
| Line Item | FY2025 | FY2023 | FY2022 | FY2021 | FY2020 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.8M | $10.0K | $75.0K | $1.2M | $10.2M | $18.5K | $20.1M | $15.0M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $138.1M | $20.1M | $28.4M | $47.5M | $44.9M | $23.3M | $25.1M | $19.6M |
| SG&A Expense | $25.4M | $19.2M | $19.1M | $17.1M | $16.7M | $8.7M | $7.8M | $6.6M |
| Operating Income | $-152.6M | $-39.3M | $-47.4M | $-63.4M | $-51.5M | $-31.9M | $-12.8M | $-11.1M |
| Operating Margin | -1,407.5% | -392,752.9% | -63,204.4% | -5,470.7% | -506.8% | -172,505.3% | -63.7% | -74.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-151.9M | — | — | — | — | — | — | — |
| Income Tax Expense | $2.0M | — | — | — | — | — | — | — |
| Net Income | $-153.9M | $-36.9M | $-46.7M | $-63.4M | $-51.0M | $-31.8M | $-12.8M | $-11.1M |
| Net Margin | -1,419.6% | -368,994.2% | -62,251.7% | -5,469.0% | -502.1% | -171,945.1% | -63.6% | -74.0% |
| EPS (Basic) | — | $-0.58 | $-0.89 | $-1.23 | $-1.12 | $-1.50 | $-0.67 | $-0.60 |
| EPS (Diluted) | — | $-0.58 | $-0.89 | $-1.23 | $-1.12 | $-1.50 | $-0.67 | $-0.60 |
| Shares Outstanding (Basic) | 27.6M | 63.3M | 52.5M | 51.5M | 45.7M | 23.3M | 19.1M | 18.5M |
| Shares Outstanding (Diluted) | 27.6M | 63.3M | 52.5M | 51.5M | 45.7M | 23.3M | 19.1M | 18.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |